newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • AEON Biopharma received FDA Type 2b feedback clarifying its integrated biosimilar strategy for ABP-450, combining analytical assessment, human pharmacodynamic studies, & existing comparative clinical evidence
  • The company submitted an Investigational New Drug (IND) application for a comparative Compound Muscle Action Potential (CMAP) pharmacodynamic study planned to initiate in Q1 2027
  • Expanded analytical data demonstrates approximately 98% coverage of the core 150 kDa neurotoxin sequence with 100% amino acid identity across all analyzed regions compared to BOTOX®
  • AEON secured approximately $6.2 million in gross proceeds from the exercise of two-year milestone warrants to fund ongoing ABP-450 development
  • The company appointed Paul Lee, M.D., Ph.D., former Deputy Director of the FDA's Office of Neuroscience, as acting Chief Regulatory Officer
  • The FDA indicated that previously completed comparative clinical studies by Daewoong Pharmaceutical for indications such as blepharospasm & upper limb spasticity may be submitted as supportive evidence subject to scientific bridging
  • Pilot forced degradation studies showed ABP-450 & BOTOX® lost potency at comparable rates under thermal stress & exhibited similar methionine site modifications under oxidative stress
  • AEON reported cash & cash equivalents of $11.4 million as of September 30, 2026, excluding the $6.2 million warrant proceeds received in the fourth quarter
  • The company expects its combined cash & warrant proceeds to fund operations into the second quarter of 2027
  • Planned milestones for 2027 include advancing comparative analytical studies, initiating the CMAP pharmacodynamic study in Q1, & starting a multi-lot forced degradation comparability study in the first half of the year
Company
AEON Biopharma Inc
Keywords
NYSE:AEON, AEON Biopharma Inc